



## Bangkok Chain Hospital

(BCH.BK/BCH TB)\*

## Outperform · Maintained

Price as of 26 Jul 2022	20.00
12M target price (Bt/shr)	28.00
Unchanged/Revised up(down)(%)	Unchanged
Upside/downside (%)	40.0

## Key messages

เราคาดว่ากำไรสุทธิของ BCH ใน 2Q65F จะอยู่ที่ 1.18 พันล้านบาท (+2.6% YoY, -42.0% QoQ), คิดเป็น 26.2% ของประมาณการกำไรเต็มปีของเราที่ 4.49 พันล้านบาท สำหรับในระลอกต่อไป เราคาดว่าโมเมนตัมธุรกิจที่ไม่เกี่ยวกับ COVID ของบริษัทจะเป็นบวกมากขึ้นเนื่องจากรัฐบาลไทยประกาศให้ COVID-19 เป็นโรคประจำถิ่นตั้งแต่เดือนกรกฎาคม เรายังคงประมาณการกำไรสุทธิปีนี้เอาไว้เท่าเดิมที่ 4.49 พันล้านบาท (-34.4% YoY) และปี 2566F ที่ 2.69 พันล้านบาท (-40.1% YoY) เรายังคงคำแนะนำซื้อและประเมินราคาเป้าหมาย DCF ปี 2565 ที่ 28.00 บาท (ใช้ WACC ที่ 7.5% และ TG ที่ 3.0%)


## Trading data

Mkt cap (Btbn/US\$m)	50/1,363
Outstanding shares (mn)	2,494
Foreign ownership (mn)	198
3M avg. daily trading (mn)	17
52-week trading range (Bt)	18.0-26.3
Performance (%)	3M 6M 12M
Absolute	(9.5) 9.9 (23.5)
Relative	(3.5) 15.2 (24.6)

## Quarterly EPS

Bt	Q1	Q2	Q3	Q4
2019	0.10	0.10	0.16	0.10
2020	0.10	0.11	0.17	0.11
2021	0.13	0.46	1.16	0.99
2022	0.81			

## Share price chart



Parin Kitchatornpitak  
66.2658.8888 Ext. 8858  
parink@kgi.co.th

## ประมาณการ 2Q65F: กำไรจะเพิ่มขึ้นเล็กน้อย YoY

## Event

ประมาณการ 2Q65F

## Impact

คาดว่าผลการดำเนินงานใน 2Q65F จะกลับสู่ระดับปกติ

เราคาดว่ากำไรสุทธิของ BCH ใน 2Q65F จะอยู่ที่ 1.18 พันล้านบาท (+2.6% YoY, -42.0% QoQ), คิดเป็น 26.2% ของประมาณการกำไรเต็มปีของเราที่ 4.49 พันล้านบาท

i) กำไรจะทรงตัว YoY เราคาดว่ารายได้จะอยู่ที่ 5.32 พันล้านบาท (+23.2% YoY, -25.0% QoQ) ในขณะที่คาดว่าอัตรากำไรขั้นต้นจะลดลงเหลือ 40.0% จาก 46.3% ใน 2Q64 และ 45.1% ใน 1Q65 เราคาดว่าผลการดำเนินงานโดยรวมจะไม่น่าตื่นเต้น เพราะความรุนแรงของสถานการณ์ COVID-19 ลดลง QoQ อย่างไรก็ตาม เราคิดว่า BCH จะได้โมเมนตัมบวกจากการฟื้นตัวของผู้ป่วยที่ไม่เกี่ยวกับ COVID-19 เพราะมีอุปสงค์ pent-up demand จากการเลื่อนรับการรักษาในช่วงที่ COVID ระบาดหนัก แต่ในอีกด้านหนึ่ง เราคาดว่ารายได้จากผู้ป่วย COVID-19 จะลดลง QoQ ตามจำนวนผู้ป่วยที่ลดลง และอัตราการจ่ายเงินที่ลดลงตามการใช้เกณฑ์ UCEP ใหม่ นอกจากนี้ เรายังคาดว่าบริษัทจะสามารถคุมต้นทุน และค่าใช้จ่ายได้ดี

ii) รายได้ที่เกี่ยวข้องกับ COVID-19 จะคิดเป็น 50% ของรายได้รวมใน 2Q65F เนื่องจากความรุนแรงของสถานการณ์ COVID-19 ลดลง ใน 2Q65 สัดส่วนรายได้จากการบริการรักษาโรคทั่วไปกับรายได้จากธุรกิจที่เกี่ยวข้องกับ COVID-19 จึงน่าจะอยู่ที่ 50:50 ใน 2Q64F จาก 43:57 ใน 1Q65

อยู่ในช่วงกลับสู่ภาวะปกติตามที่คาดไว้ก่อนหน้านี้

สำหรับในระลอกต่อไป เราคาดว่าโมเมนตัมธุรกิจที่ไม่เกี่ยวกับ COVID ของบริษัทจะเป็นบวกมากขึ้น เนื่องจากรัฐบาลไทยประกาศให้ COVID-19 เป็นโรคประจำถิ่นตั้งแต่เดือนกรกฎาคม ทั้งนี้ แม้ว่าจำนวนผู้ติดเชื้อจะยังสูงใน 3Q65 แต่การระบาดไม่รุนแรงเท่ากับรอบก่อน ๆ ดังนั้น เราจึงเชื่อว่าสถานการณ์โรคระบาดน่าจะทรงตัว หรือลดลง QoQ ใน 2H65 โดยปัจจัยสำคัญที่จะช่วยขับเคลื่อนผลการดำเนินงานจากธุรกิจหลักของ BCH ให้ดีขึ้นได้แก่ i) อุปสงค์ pent-up demand ที่เพิ่มขึ้นจากการเลื่อนรับการรักษาในช่วงก่อนหน้านี้ ii) จำนวนผู้ป่วยประกันสังคมเพิ่มขึ้น (มีผู้ป่วยลงทะเบียน 956,000 รายเมื่อสิ้นงวด 1Q65 เพิ่มขึ้นจาก 892,000 รายเมื่อสิ้นงวด 2Q64) และ iii) platform โรงพยาบาลดีขึ้น (มีการครบแต่งปรับปรุงใหม่ และ มาตรฐานโรงพยาบาลดีขึ้น)

คงประมาณการกำไรปี FY65-66F เอาไว้เท่าเดิม

เมื่ออิงจากประมาณการกำไรใน 1H65 เรายังคงประมาณการกำไรสุทธิปีนี้เอาไว้เท่าเดิมที่ 4.49 พันล้านบาท (-34.4% YoY) และปี 2566F ที่ 2.69 พันล้านบาท (-40.1% YoY)

## Valuation &amp; Action

ถึงแม้ว่าสถานการณ์ COVID-19 จะผ่านช่วงที่เลวร้ายที่สุดไปแล้ว แต่เรายังชอบแนวโน้มการเติบโตจากภายในของบริษัทที่จะมาจาก i) ผู้ป่วยกลุ่มที่ไม่เกี่ยวกับ COVID ในปี 2565 และ ii) platform ธุรกิจที่แข็งแกร่งสำหรับรองรับทั้งผู้ป่วยชาวไทย และต่างชาติ เรายังคงคำแนะนำซื้อ และประเมินราคาเป้าหมาย DCF ปี 2565 ที่ 28.00 บาท (ใช้ WACC ที่ 7.5% และ TG ที่ 3.0%)

## Risks

COVID-19 ระบาด, เกิดปัญหาเสถียรภาพทางการเมืองไทยรอบใหม่, เกิดเหตุก่อการร้ายครั้งใหญ่

## Key financials and valuations

	Dec-19A	Dec-20A	Dec-21A	Dec-22F	Dec-23F
Revenue (Bt mn)	8,880	8,928	21,405	17,124	13,699
Gross profit (Bt mn)	2,828	2,953	10,844	7,706	4,795
EBIT (Bt mn)	1,715	1,837	9,505	6,456	3,932
Net profit (Bt mn)	1,135	1,229	6,846	4,491	2,688
EPS (Bt)	0.46	0.49	2.74	1.80	1.08
DPS (Bt)	0.23	0.23	1.20	0.81	0.49
EPS growth (%)	4.2	8.3	456.9	(34.4)	(40.1)
P/E (x)	37.6	27.6	7.3	11.1	18.5
P/B (x)	7.1	6.5	3.5	3.2	3.1
EV/EBITDA (x)	22.8	21.4	5.0	6.8	10.2
Net Debt to Equity (%)	65.9	83.5	12.5	4.4	0.8
Dividend Yield (%)	1.2	1.2	6.0	4.1	2.4
Return on Avg. Equity (%)	16.3	16.1	47.9	28.9	16.9

Source: Company data, KGI Securities Research

\*The Company may be issuer of Derivative Warrants on these securities.

http://research.kgi.com; Bloomberg: KGI <GO> Please see back page for disclaimer

**Figure 1: BCH's 2Q22F earnings preview**

Bt mn	2Q22F	2Q21	YoY (%)	1Q22	QoQ (%)	1H22F	1H21	YoY (%)
Sale revenue	5,315	4,313	23.2	7,087	(25.0)	12,403	6,630	87.1
Operating cost	(3,189)	(2,318)	37.6	(3,890)	(18.0)	(7,079)	(3,937)	79.8
Gross profit	2,126	1,995	6.6	3,197	(33.5)	5,324	2,692	97.7
SG&A	(478)	(401)	19.4	(491)	(2.6)	(970)	(691)	40.2
EBIT	1,668	1,613	3.4	2,738	(39.1)	4,406	2,088	111.0
Net profit	1,176	1,146	2.6	2,028	(42.0)	3,204	1,469	118.0
EPS (Bt)	0.47	0.46	2.6	0.81	(42.0)	1.28	0.59	118.0
Percent	2Q22F	2Q21	YoY (ppts)	1Q22	QoQ (ppts)	1H22F	1H21	YoY (ppts)
Gross margin	40.0	46.3	(6.3)	45.1	(5.1)	42.9	40.6	2.3
SG&A/Sales	9.0	9.3	(0.3)	6.9	2.1	7.8	10.4	(2.6)
Net profit margin	22.1	26.6	(4.4)	28.6	(6.5)	25.8	22.2	3.7

	2Q22F	2Q21	YoY (%)	1Q22	QoQ (%)
<i>Revenue by hospital breakdown</i>					
Kasemrad (Bt mn)	4,146	3,272	26.7	5,535	(25.1)
Karunvej (Bt mn)	505	386	30.9	695	(27.3)
WMC (Bt mn)	664	655	1.4	858	(22.5)
<i>Revenue by patient type</i>					
OPD (Bt mn)	1,595	1,841	(13.4)	2,072	(23.1)
IPD (Bt mn)	2,658	1,747	52.1	3,565	(25.4)
SS (Bt mn)	1,063	725	46.5	1,449	(26.6)


  

	2Q22F	2Q21	YoY (ppts)	1Q22	QoQ (ppts)
<i>Revenue by hospital breakdown</i>					
Kasemrad (%)	78.0	75.9	2.1	78.1	(0.1)
Karunvej (%)	9.5	8.9	0.6	9.8	(0.3)
WMC (%)	12.5	15.2	(2.7)	12.1	0.4
<i>Revenue by patient type</i>					
OPD (%)	30.0	42.7	(12.7)	29.2	0.8
IPD (%)	50.0	40.5	9.5	50.3	(0.3)
SS (%)	20.0	16.8	3.2	20.4	(0.4)


Source: Company data, KGI Securities Research

**Figure 2: Revenue breakdown for 2Q22F**

Percent



Source: Company data, KGI Securities Research


**Figure 3: WMC's 1Q22 revenue mix by nationality**


Source: Company data

**Figure 4: COVID and non-COVID revenues each quarter during 2021 and 1Q22**

Visiting Number (% to total visit)	1Q2021	2Q2021	3Q2021	4Q2021	1Q2022
Non-COVID (Cash + SSO)	85.40%	54.06%	51.18%	55.92%	43.07%
Alternative Vaccine (Moderna)	-	-	-	25.15%	20.98%
COVID-19 Screening + Test & Go	13.78%	43.45%	39.85%	16.89%	24.77%
COVID-19 Hospital & Hospitel & Home i	0.03%	1.93%	8.56%	1.56%	10.78%
Alternative Quarantine (AQ)	0.75%	0.55%	0.39%	0.45%	0.37%
Alternative Hospital Quarantine (AHQ)	0.03%	0.01%	0.01%	0.02%	0.03%
<b>Total Visits</b>	<b>899,440</b>	<b>1,354,360</b>	<b>1,317,620</b>	<b>1,372,300</b>	<b>1,846,700</b>

Source: Company data

**Figure 5: COVID-19 infections should have peaked in March 2022**


Source: CCSA, KGI Securities Research

**Figure 6: Earlier-than-expected performances for three new hospitals**



Source: Company data

**Figure 7: Company profile**

Bangkok Chain Hospital (BCH) was established in 1993 with initial capital of Bt150mn. In 2013, the company expanded with three additional hospitals including i) World Medical Hospital (WMH) on Chaengwattana Road, which focuses on the high-end market from both local and international patients with international standards and modern medical equipment, and ii) acquisition of two Navanakorn Hospitals in Pathumthani and Ayudhaya. Currently, the company operates 11 hospitals and two poly clinics within the network with 2,328 registered beds. The company serves all types of customers both in Bangkok and upcountry.


Source: Company data

**Figure 8: Shareholding structure**




Source: Company data, KGI Securities Research

**Figure 9: Revenue contribution by brand in 2020**




Source: Company data, KGI Securities Research

**Figure 10: Revenue contribution by brand in 2021**




Source: Company data, KGI Securities Research

**Figure 11: Revenue contribution by patient type in 2020**




Source: Company data, KGI Securities Research

**Figure 12: Revenue contribution by patient type in 2021**




Source: Company data, KGI Securities Research

**Figure 13: WMC's 2020 revenue breakdown by patient type**



Source: Company data, KGI Securities Research

**Figure 14: WMC's 2021 revenue breakdown by patient type**



Source: Bloomberg, KGI Securities Research

**Quarterly Income Statement**

	Mar-19A	Jun-19A	Sep-19A	Dec-19A	Mar-20A	Jun-20A	Sep-20A	Dec-20A	Mar-21A	Jun-21A	Sep-21A	Dec-21A	Mar-22A
<b>Income Statement (Bt mn)</b>													
<b>Revenue</b>	<b>2,078</b>	<b>2,137</b>	<b>2,469</b>	<b>2,196</b>	<b>2,178</b>	<b>2,083</b>	<b>2,359</b>	<b>2,308</b>	<b>2,316</b>	<b>4,313</b>	<b>7,959</b>	<b>6,816</b>	<b>7,087</b>
Cost of Goods Sold	(1,444)	(1,483)	(1,590)	(1,535)	(1,515)	(1,392)	(1,496)	(1,571)	(1,619)	(2,318)	(3,689)	(2,935)	(3,890)
<b>Gross Profit</b>	<b>635</b>	<b>654</b>	<b>879</b>	<b>661</b>	<b>663</b>	<b>691</b>	<b>863</b>	<b>737</b>	<b>698</b>	<b>1,995</b>	<b>4,271</b>	<b>3,881</b>	<b>3,197</b>
<b>Operating Expenses</b>	<b>(288)</b>	<b>(306)</b>	<b>(317)</b>	<b>(320)</b>	<b>(293)</b>	<b>(280)</b>	<b>(276)</b>	<b>(363)</b>	<b>(291)</b>	<b>(401)</b>	<b>(367)</b>	<b>(411)</b>	<b>(491)</b>
Other incomes	28	30	32	28	20	21	20	35	68	19	19	24	32
<b>Operating Profit</b>	<b>374</b>	<b>378</b>	<b>594</b>	<b>369</b>	<b>389</b>	<b>432</b>	<b>606</b>	<b>409</b>	<b>475</b>	<b>1,613</b>	<b>3,923</b>	<b>3,494</b>	<b>2,738</b>
<b>Non-Operating Income</b>	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Income	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Non-op Income	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>Non-Operating Expenses</b>	<b>(32)</b>	<b>(34)</b>	<b>(35)</b>	<b>(29)</b>	<b>(30)</b>	<b>(32)</b>	<b>(35)</b>	<b>(35)</b>	<b>(28)</b>	<b>(35)</b>	<b>(40)</b>	<b>(48)</b>	<b>(48)</b>
Interest Expense	(32)	(34)	(35)	(29)	(30)	(32)	(35)	(35)	(28)	(35)	(40)	(48)	(48)
Other Non-op Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Investment Income/(Loss)	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>Pre-tax Profit</b>	<b>342</b>	<b>343</b>	<b>559</b>	<b>339</b>	<b>359</b>	<b>400</b>	<b>572</b>	<b>374</b>	<b>448</b>	<b>1,578</b>	<b>3,883</b>	<b>3,446</b>	<b>2,690</b>
Current taxation	(59)	(65)	(101)	(62)	(63)	(75)	(107)	(68)	(84)	(312)	(772)	(679)	(542)
Minorities	(35)	(36)	(56)	(36)	(37)	(46)	(52)	(28)	(40)	(121)	(215)	(286)	(120)
Extraordinary items	-	1	-	(1)	-	-	-	-	-	-	-	-	-
<b>Net Profit</b>	<b>248</b>	<b>244</b>	<b>402</b>	<b>241</b>	<b>259</b>	<b>279</b>	<b>413</b>	<b>278</b>	<b>324</b>	<b>1,146</b>	<b>2,896</b>	<b>2,480</b>	<b>2,028</b>
EPS (Bt)	0.1	0.1	0.2	0.1	0.1	0.1	0.2	0.1	0.1	0.5	1.2	1.0	0.8
<b>Margins (%)</b>													
Gross profit margin	30.5	30.6	35.6	30.1	30.4	33.2	36.6	31.9	30.1	46.3	53.7	56.9	45.1
Operating margin	18.0	17.7	24.1	16.8	17.9	20.8	25.7	17.7	20.5	37.4	49.3	51.3	38.6
Net profit margin	11.9	11.4	16.3	11.0	11.9	13.4	17.5	12.1	14.0	26.6	36.4	36.4	28.6
<b>Growth (%)</b>													
Revenue growth	14.0	11.4	10.8	4.3	4.8	(2.5)	(4.5)	5.1	6.4	107.1	237.4	195.3	205.9
Operating growth	10.0	(0.5)	13.6	(11.4)	4.0	14.4	2.1	11.0	22.0	273.2	546.8	754.5	476.4
Net profit growth	15.6	(2.4)	12.8	(10.3)	4.4	14.2	2.8	15.6	24.9	311.3	600.7	791.2	526.5

Source: KGI Securities Research

**Balance Sheet**

As of 31 Dec (Bt mn)	2019	2020	2021	2022F	2023F
<b>Total Assets</b>	<b>14,116</b>	<b>16,527</b>	<b>26,384</b>	<b>28,550</b>	<b>29,387</b>
<b>Current Assets</b>	2,967	3,538	13,541	13,265	12,685
Cash & ST Investments	792	944	4,520	5,744	6,423
Inventories	231	250	437	483	457
Accounts Receivable	1,853	2,335	7,820	6,256	5,005
Others	90	10	764	782	800
<b>Non-current Assets</b>	11,149	12,989	12,842	15,285	16,702
LT Investments	1,006	999	487	487	487
Net fixed Assets	9,944	11,767	12,119	14,510	15,961
Others	198	223	237	289	255
<b>Total Liabilities</b>	<b>7,137</b>	<b>8,901</b>	<b>12,078</b>	<b>13,027</b>	<b>13,442</b>
<b>Current Liabilities</b>	2,186	5,667	7,848	8,435	8,792
Accounts Payable	852	784	1,358	1,542	1,458
ST Borrowings	718	4,289	2,980	3,032	3,087
Others	615	595	3,510	3,860	4,247
<b>Long-term Liabilities</b>	4,952	3,234	4,231	4,592	4,650
Long-term Debts	4,759	3,027	4,060	4,142	4,225
Others	192	207	170	450	426
<b>Shareholders' Equity</b>	<b>6,978</b>	<b>7,626</b>	<b>14,306</b>	<b>15,523</b>	<b>15,945</b>
Common Stock	2,494	2,494	2,494	2,494	2,494
Capital Surplus	645	645	645	645	645
Retained Earnings	2,935	3,589	9,696	11,207	11,875
Others	905	899	1,471	1,178	932

Source: KGI Securities Research

**Key Ratios**

Year to 31 Dec (Bt mn)	2019	2020	2021	2022F	2023F
<b>Growth (% YoY)</b>					
Sales	10.0	0.5	139.8	(20.0)	(20.0)
OP	3.4	7.1	417.4	(32.1)	(39.1)
EBITDA	6.5	10.1	296.3	(29.0)	(33.6)
NP	4.2	8.3	456.9	(34.4)	(40.1)
EPS	4.2	8.3	456.9	(34.4)	(40.1)
<b>Profitability (%)</b>					
Gross Margin	31.8	33.1	50.7	45.0	35.0
Operating Margin	19.3	20.6	44.4	37.7	28.7
EBITDA Margin	26.8	29.3	48.5	43.1	35.7
Net Profit Margin	12.8	13.8	32.0	26.2	19.6
ROAA	8.0	7.4	25.9	15.7	9.1
ROAE	16.3	16.1	47.9	28.9	16.9
<b>Stability</b>					
Gross Debt/Equity (%)	78.5	95.9	49.2	46.2	45.9
Net Debt/Equity (%)	65.9	83.5	12.5	4.4	0.8
Interest Coverage (x)	13.2	13.1	13.9	62.8	41.4
Interest & ST Debt Coverage (x)	2.0	0.4	3.0	2.0	1.2
Cash Flow Interest Coverage (x)	14.6	14.1	41.4	25.8	14.6
Cash Flow/Interest & ST Debt (x)	2.2	0.4	2.0	1.3	0.7
Current Ratio (x)	1.4	0.6	1.7	1.6	1.4
Quick Ratio (x)	1.3	0.6	1.7	1.5	1.4
Net Debt (Bt mn)	4,877	6,578	2,691	1,880	1,314
<b>Per Share Data (Bt)</b>					
EPS	0.5	0.5	2.7	1.8	1.1
CFPS	0.3	0.4	1.8	2.3	2.6
BVPS	2.8	3.1	5.7	6.2	6.4
SPS	3.6	3.6	8.6	6.9	5.5
EBITDA/Share	1.0	1.1	4.2	3.0	2.0
DPS	0.2	0.2	1.2	0.8	0.5
<b>Activity</b>					
Asset Turnover (x)	0.7	0.6	1.0	0.6	0.5
Days Receivables	76.2	95.5	133.3	133.3	133.3
Days Inventory	9.5	10.2	7.4	10.3	12.2
Days Payable	51.4	47.9	46.9	59.8	59.8
Cash Cycle	34.3	57.8	93.9	83.9	85.7

Source: KGI Securities Research

**Profit & Loss**

Year to 31 Dec (Bt mn)	2019	2020	2021	2022F	2023F
<b>Sales</b>	<b>8,880</b>	<b>8,928</b>	<b>21,405</b>	<b>17,124</b>	<b>13,699</b>
Cost of Goods Sold	(6,052)	(5,975)	(10,561)	(9,418)	(8,904)
<b>Gross Profit</b>	<b>2,828</b>	<b>2,953</b>	<b>10,844</b>	<b>7,706</b>	<b>4,795</b>
Operating Expenses	(1,114)	(1,116)	(1,339)	(1,250)	(863)
<b>Operating Profit</b>	<b>1,715</b>	<b>1,837</b>	<b>9,505</b>	<b>6,456</b>	<b>3,932</b>
Net Interest	(131)	(132)	(151)	(156)	(160)
Interest Income	0	0	0	0	0
Interest Expense	(131)	(132)	(151)	(156)	(160)
Net Investment Income/(Loss)	0	0	0	0	0
Net other Non-op. Income/(Loss)	118	96	131	120	96
Net Extraordinaries	(163)	(163)	(661)	(612)	(367)
Pretax Income	1,584	1,705	9,354	6,300	3,771
Income Taxes	(286)	(313)	(1,846)	(1,197)	(717)
<b>Net Profit</b>	<b>1,135</b>	<b>1,229</b>	<b>6,846</b>	<b>4,491</b>	<b>2,688</b>
EBITDA	2,379	2,619	10,379	7,373	4,895
<b>EPS (Bt)</b>	<b>0.46</b>	<b>0.49</b>	<b>2.74</b>	<b>1.80</b>	<b>1.08</b>

Source: KGI Securities Research

**Cash Flow**


Year to 31 Dec (Bt mn)	2019	2020	2021	2022F	2023F
<b>Operating Cash Flow</b>	1,902	1,863	6,256	4,018	2,339
Net Profit	1,135	1,229	6,846	4,491	2,688
Depreciation & Amortization	665	782	874	918	963
Change in Working Capital	(198)	(509)	(2,938)	(2,938)	(2,938)
Others	301	361	1,475	1,549	1,626
<b>Investment Cash Flow</b>	(1,729)	(2,597)	(1,495)	(741)	(667)
Net CAPEX	(1,741)	(2,671)	(1,495)	(1,540)	(1,587)
Change in LT Investment	(0)	(0)	(0)	(0)	(0)
Change in Other Assets	12	74	0	799	920
<b>Free Cash Flow</b>	173	(734)	4,761	3,277	1,672
<b>Financing Cash Flow</b>	(27)	886	(1,185)	(2,054)	(993)
Change in Share Capital	0	0	0	0	0
Net Change in Debt	289	1,824	607	26	28
Change in Other LT Liab.	(315)	(939)	(1,792)	(2,081)	(1,021)
<b>Net Cash Flow</b>	147	151	3,576	1,223	679

Source: KGI Securities Research

**Rates of Return on Invested Capital**

Year	1- $\frac{\text{COGS}}{\text{Revenue}}$	+ $\frac{\text{Depreciation}}{\text{Revenue}}$	+ $\frac{\text{Operating Exp.}}{\text{Revenue}}$	= <b>Operating Margin</b>
2019	68.2%	7.5%	13.9%	10.5%
2020	66.9%	8.8%	13.6%	10.7%
2021	49.3%	4.1%	6.9%	39.7%
2022F	55.0%	5.4%	8.0%	31.6%
2023F	65.0%	7.0%	7.0%	21.0%
Year	1/ $\frac{\text{Working Capital}}{\text{Revenue}}$	+ $\frac{\text{Net PPE}}{\text{Revenue}}$	+ $\frac{\text{Other Assets}}{\text{Revenue}}$	= <b>Capital Turnover</b>
2019	0.23	1.08	1.59	0.34
2020	0.31	1.28	1.85	0.29
2021	0.53	0.55	1.23	0.43
2022F	0.64	0.83	1.67	0.32
2023F	0.76	1.14	2.15	0.25
Year	$\frac{\text{Operating Margin}}{\text{Capital Turnover}}$	x	$\frac{\text{Cash Tax Rate}}{\text{After-tax Return on Inv. Capital}}$	=
2019	10.5%	0.3	81.9%	3.0%
2020	10.7%	0.3	81.7%	2.5%
2021	39.7%	0.4	80.3%	13.8%
2022F	31.6%	0.3	81.0%	8.2%
2023F	21.0%	0.2	81.0%	4.2%

Source: KGI Securities Research

**Bangkok Chain Hospital – Recommendation & target price history**


Source: KGI Securities Research



# Corporate Governance Report of Thai Listed Companies



## Companies with Excellent CG Scoring

Stock	Company name	Stock	Company name	Stock	Company name
AAV	ASIA AVIATION	EGCO	ELECTRICITY GENERATING	PTTEP	PTT EXPLORATION AND PRODUCTION
ADVANC	ADVANCED INFO SERVICE	GFPT	GFPT	PTTGC	PTT GLOBAL CHEMICAL
AMA	AMA MARINE	GGC	GLOBAL GREEN CHEMICALS	PYLON	PYLON
AMATA	AMATA CORPORATION	GPSC	GLOBAL POWER SYNERGY	QH	QUALITY HOUSES
ANAN	ANANDA DEVELOPMENT	HANA	HANA MICROELECTRONICS	RATCH	RATCHABURI ELECTRICITY GENERATING HOLDING
AOT	AIRPORTS OF THAILAND	HMPRO	HOME PRODUCT CENTER	RS	RS
AP	ASIAN PROPERTY DEVELOPMENT	INTUCH	SHIN CORPORATION	SCB	THE SIAM COMMERCIAL BANK
BANPU	BANPU	IRPC	IRPC	SCC	THE SIAM CEMENT
BCP	THE BANGCHAK PETROLEUM	IVL	INDORAMA VENTURES	SCCC	SIAM CITY CEMENT
BCPG	BCPG	KBANK	KASIKORNBANK	SEAFCO	SEAFCO
BDMS	BANGKOK DUSIT MEDICAL SERVICES	KCE	KCE ELECTRONICS	SMPC	SAHAMITR PRESSURE CONTAINER
BEC	BEC WORLD	KKP	KIATNAKIN BANK	SPALI	SUPALAI
BEM	BANGKOK EXPRESSWAY AND METRO	KTB	KRUNG THAI BANK	SPRC	STAR PETROLEUM REFINING
BGRIM	B. GRIMM POWER	KTC	KRUNGTHAI CARD	SVI	SVI
BPP	BANPU POWER	LH	LAND AND HOUSES	TACC	T.A.C. CONSUMER
BTS	BTS GROUP HOLDINGS	LPN	L.P.N. DEVELOPMENT	TCAP	THANACHART CAPITAL
CENTEL	CENTRAL PLAZA HOTEL	MAKRO	SIAM MAKRO	THCOM	THAICOM
CK	CH. KARNCHANG	MBK	MBK	TISCO	TISCO FINANCIAL GROUP
CKP	CK POWER	MINT	MINOR INTERNATIONAL	TOP	THAI OIL
CPALL	CP ALL	MTC	MUANGTHAI CAPITAL	TRUE	TRUE CORPORATION
CPF	CHAROEN POKPHAND FOODS	PLANB	PLAN B MEDIA	TTB	TMBTHANACHART BANK
CPN	CENTRAL PATTANA	PSH	PRUKSA HOLDING	VGI	VGI GLOBAL MEDIA
DELTA	DELTA ELECTRONICS (THAILAND)	PTG	PTG ENERGY	WHA	WHA CORPORATION
DTAC	TOTAL ACCESS COMMUNICATION	PTT	PTT	WHAUP	



## Companies with Very Good CG Scoring

Stock	Company name	Stock	Company name	Stock	Company name
BAM	BANGKOK COMMERCIAL ASSET MANAGEMENT	GULF	GULF ENERGY DEVELOPMENT	SAPPE	SAPPE
BBL	BANGKOK BANK	JMT	JMT NETWORK SERVICES	SAWAD	SRI SAWAD POWER 1979
CBG	CARABAO GROUP	LPH	LADPRAO GENERAL HOSPITAL	SINGER	SINGER THAILAND
CHG	CHULARAT HOSPITAL	M	MK RESTAURANT GROUP	SPA	SIAM WELLNESS GROUP
COM7	COM7	MAJOR	MAJOR CINEPLEX GROUP	TFG	THAIFOODS GROUP
DOHOME	DOHOME	MEGA	MEGA LIFESCIENCES	TKN	TAOKAENOI FOOD & MARKETING
ERW	THE ERAWAN GROUP	NETBAY	NETBAY	ZEN	ZEN CORPORATION GROUP
GLOBAL	SIAM GLOBAL HOUSE	OSP	OSOTSPA		



## Companies with Good CG Scoring

Stock	Company name	Stock	Company name	Stock	Company name
BCH	BANGKOK CHAIN HOSPITAL	ESSO	ESSO (THAILAND)	SF	SIAM FUTURE DEVELOPMENT
BH	BUMRUNGRAD HOSPITAL	HUMAN	HUMANICA	SISB	SISB
EKH	EKACHAI MEDICAL CARE	RBF	R&B FOOD SUPPLY	TPCH	TPC POWER HOLDING

## Companies classified Not in the three highest score groups

Stock	Company name	Stock	Company name	Stock	Company name
IIG	I&I GROUP	OR	PTT OIL AND RETAIL BUSINESS	STGT	SRI TRANG GLOVES (THAILAND)
KEX	KERRY EXPRESS (THAILAND)	STEC	SINO-THAI ENGINEERING AND CONSTRUCTION		

Source: www.thai-iod.com

**Disclaimer:** The disclosure of the survey result of the Thai Institute of Directors Association ("IOD") regarding corporate governance is made pursuant to the policy of the Office of the Securities and Exchange Commission. The survey of the IOD is based on the information of a company listed on the Stock Exchange of Thailand and the Market for Alternative Investment disclosed to the public and able to be accessed by a general public investor. The result, therefore, is from the perspective of a third party. It is not an assessment of operation and is not based on inside information. The survey result is as of the date appearing in the Corporate Governance Report of Thai Listed Companies. As a result, the survey result may be changed after that date or when there is any change to the relevant information. Nevertheless, KGI Securities (Thailand) Public Company Limited (KGI) does not confirm, verify, or certify the accuracy and completeness of such survey result.



## Anti-corruption Progress Indicator

### Level 5: Extended

Stock	Company name	Stock	Company name	Stock	Company name
ADVANC	ADVANCED INFO SERVICE	GLOBAL	SIAM GLOBAL HOUSE	QH	QUALITY HOUSES
ANAN	ANANDA DEVELOPMENT	GPSC	GLOBAL POWER SYNERGY	RATCH	RATCHABURI ELECTRICITY GENERATING HOLDING
BBL	BANGKOK BANK	HMPRO	HOME PRODUCT CENTER	ROBINS	ROBINSON DEPARTMENT STORE
BCH	BANGKOK CHAIN HOSPITAL	IRPC	IRPC	SCC	THE SIAM CEMENT
BDMS	BANGKOK DUSIT MEDICAL SERVICES	KBANK	KASIKORNBANK	SIRI	SANSIRI
BIGC	BIG C SUPERCENTER	KCE	KCE ELECTRONICS	SPALI	SUPALAI
CK	CH. KARNCHANG	KKP	KIATNAKIN BANK	STEC	SINO-THAI ENGINEERING AND CONSTRUCTION
DCC	DYNASTY CERAMIC	KTB	KRUNG THAI BANK	TCAP	THANACHART CAPITAL
DELTA	DELTA ELECTRONICS (THAILAND)	LPH	LADPRAO GENERAL HOSPITAL	TISCO	TISCO FINANCIAL GROUP
DRT	DIAMOND ROOFING TILES	PACE	PACE DEVELOPMENT CORPORATION	TMT	THAI METAL TRADE
EGCO	ELECTRICITY GENERATING	PTT	PTT	TOP	THAI OIL
GFPT	GFPT	PTTGC	PTT GLOBAL CHEMICAL		

### Level 4: Certified

Stock	Company name	Stock	Company name	Stock	Company name
AAV	ASIA AVIATION	ERW	THE ERAWAN GROUP	SAPPE	SAPPE
AP	ASIAN PROPERTY DEVELOPMENT	GLOW	GLOW ENERGY	SAWAD	SRISAWAD POWER 1979
BA	BANGKOK AIRWAYS	GUNKUL	GUNKUL ENGINEERING	SCB	THE SIAM COMMERCIAL BANK
BANPU	BANPU	ILINK	INTERLINK COMMUNICATION	SCN	SCAN INTER
BCP	THE BANGCHAK PETROLEUM	KTC	KRUNGTHAI CARD	SEAFECO	SEAFECO
BH	BUMRUNGRAD HOSPITAL	LH	LAND AND HOUSES	SVI	SVI
BJCHI	BJC HEAVY INDUSTRIES	LPN	L.P.N. DEVELOPMENT	TASCO	TIPCO ASPHALT
CBG	CARABAO GROUP	MAKRO	SIAM MAKRO	TKN	TAOKAENOI FOOD & MARKETING
CENTEL	CENTRAL PLAZA HOTEL	MALEE	MALEE SAMPRAN	TMB	TMB BANK
CHG	CHULARAT HOSPITAL	MINT	MINOR INTERNATIONAL	TRT	TIRATHAI
CKP	CK POWER	MODERN	MODERNFORM GROUP	TRUE	TRUE CORPORATION
CPF	CHAROEN POKPHAND FOODS	NOK	NOK AIRLINES	TVO	THAI VEGETABLE OIL
CPN	CENTRAL PATTANA	PTTEP	PTT EXPLORATION AND PRODUCTION		
DTAC	TOTAL ACCESS COMMUNICATION	PYLON	PYLON		

### Level 3: Established

Stock	Company name	Stock	Company name	Stock	Company name
BEM	BANGKOK EXPRESSWAY AND METRO	MTLS	MUANGTHAI LEASING	SPRC	STAR PETROLEUM REFINING
CPALL	CP ALL	SCI	SCI ELECTRIC		

### No progress

Stock	Company name	Stock	Company name	Stock	Company name
AOT	AIRPORTS OF THAILAND	BPP	BANPU POWER	FN	FN FACTORY OUTLET
BCPG	BCPG	BTS	BTS GROUP HOLDINGS	TPCH	TPC POWER HOLDING

Source: www.cgthailand.org

**Disclaimer:** The disclosure of the Anti-Corruption Progress Indicators of a listed company on the Stock Exchange of Thailand, which is assessed by the relevant institution as disclosed by the Office of the Securities and Exchange Commission, is made in order to comply with the policy and sustainable development plan for the listed companies. The relevant institution made this assessment based on the information received from the listed company, as stipulated in the form for the assessment of Anti-corruption which refers to the Annual Registration Statement (Form 56-1), Annual Report (Form 56-2), or other relevant documents or reports of such listed company. The assessment result is therefore made from the perspective of a third party. It is not an assessment of operation and is not based on any inside information. Since this assessment is only the assessment result as of the date appearing in the assessment result, it may be changed after that date or when there is any change to the relevant information. Nevertheless, KGI Securities (Thailand) Public Company Limited (KGI) does not confirm, verify, or certify the accuracy and completeness of the assessment result.

**KGI Locations**

<b>China</b>	Shanghai	Room 1507, Park Place, 1601 Nanjing West Road, Jingan District, Shanghai, PRC 200040
	Shenzhen	Room 24D1, 24/F, A Unit, Zhen Ye Building, 2014 Bao'annan Road, Shenzhen, PRC 518008
<b>Taiwan</b>	Taipei	700 Mingshui Road, Taipei, Taiwan Telephone 886.2.2181.8888 · Facsimile 886.2.8501.1691
<b>Hong Kong</b>		41/F Central Plaza, 18 Harbour Road, Wanchai, Hong Kong Telephone 852.2878.6888 Facsimile 852.2878.6800
<b>Thailand</b>	Bangkok	8th - 11th floors, Asia Centre Building 173 South Sathorn Road, Bangkok 10120, Thailand Telephone 66.2658.8888 Facsimile 66.2658.8014
<b>Singapore</b>		4 Shenton Way #13-01 SGX Centre 2 Singapore 068807 Telephone 65.6202.1188 Facsimile 65.6534.4826

**KGI's Ratings**

<b>Rating</b>	<b>Definition</b>
Outperform (OP)	The stock's excess return over the next twelve months is ranked in the top 40% of KGI's coverage universe in the related market (e.g. Taiwan).
Neutral (N)	The stock's excess return over the next twelve months is ranked in the range between the top 40% and the bottom 40% of KGI's coverage universe in the related market (e.g. Taiwan)
Under perform (U)	The stock's excess return over the next twelve months is ranked in the bottom 40% of KGI's coverage universe in the related market (e.g. Taiwan).
Not Rated (NR)	The stock is not rated by KGI.
Restricted (R)	KGI policy and/or applicable law regulations preclude certain types of communications, including an investment recommendation, during the course of KGI's engagement in an investment banking transaction and in certain other circumstances.  <i>Excess return = 12M target price/current price-</i>
Note	When an analyst publishes a new report on a covered stock, we rank the stock's excess return with those of other stocks in KGI's coverage universe in the related market. We will assign a rating based on its ranking. If an analyst does not publish a new report on a covered stock, its rating will not be changed automatically.

**Disclaimer**

KGI Securities (Thailand) Plc. ( "The Company" ) disclaims all warranties with regards to all information contained herein. In no event shall the Company be liable for any direct, indirect or any damages whatsoever resulting from loss of income or profits, arising by utilization and reliance on the information herein. All information hereunder does not constitute a solicitation to buy or sell any securities but constitutes our sole judgment as of this date and are subject to change without notice.